IMR Press / JIN / Volume 21 / Issue 6 / DOI: 10.31083/j.jin2106156
Open Access Original Research
Association of Early Increase in Body Temperature with Symptomatic Intracranial Hemorrhage and Unfavorable Outcome Following Endovascular Therapy in Patients with Large Vessel Occlusion Stroke
Show Less
1 Department of Neurology and Advanced National Stroke Center, Foshan Sanshui District People's Hospital, 528100 Foshan, Guangdong, China
2 Department of Neurology, Radiology, Boston University School of Medicine, Boston, MA 02118, USA
3 School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, BT7 1NN County Antrim, Northern Ireland, UK
4 Department of Radiology, Boston University School of Medicine, Boston, MA 02118, USA
5 School of Medicine, Cardiff University, CF14 4XN Wales, UK
6 Foshan Sanshui District People's Hospital, 528100 Foshan, Guangdong, China
7 School of Medicine, Shaoguan University, 512158 Shaoguan, Guangdong, China
8 Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, 530011 Nanning, Guangxi, China
9 Faculty of Humanities and Social Sciences, Macao Polytechnic University, 999078 Macao, China
*Correspondence: P2009495@ipm.edu.mo (Baoxin Chen); yangshuiquan1969@126.com (Shuiquan Yang)
Academic Editor: Giovanni Grasso
J. Integr. Neurosci. 2022, 21(6), 156; https://doi.org/10.31083/j.jin2106156
Submitted: 5 February 2021 | Revised: 8 April 2022 | Accepted: 24 April 2022 | Published: 20 September 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Introduction: The aim of this study was to investigate for possible associations between an early increase in body temperature within 24 hours of endovascular therapy (EVT) for large vessel occlusion stroke and the presence of symptomatic intracranial hemorrhage (sICH) and other clinical outcomes. Methods: This was a retrospective study of consecutive patients with large vessel occlusion stroke who were treated with EVT from August 2018 to June 2021. Patients were divided into two groups based on the presence of fever, as defined by a Peak Body Temperature (PBT) of 37.3 °C. The presence of sICH and other clinical outcomes were compared between the two groups. Results: The median NIHSS admission score (IQR) was 16.0 (12.0, 21.0), with higher NIHSS scores in the PBT 37.3 °C group than in the PBT <37.3 °C group (18 vs 14, respectively; p = 0.002). There were no differences in clinical outcomes at 3 months between patients with PBT <37.3 °C and patients with PBT between 37.3 °C and 38 °C. However, patients with PBT 38 °C had an increased risk of sICH (adjusted odds ratio (OR) = 8.8, 95% confidence interval (95% CI): 1.7–46.0; p = 0.01), increased inpatient death or hospice discharge (OR = 10.5, 95% CI: 2.0–53.9; p = 0.005), poorer clinical outcome (OR = 25.6, 95% CI: 5.2–126.8; p < 0.001), and increased 3-month mortality (OR = 6.6, 95% CI: 1.8–24.6; p = 0.01). Conclusions: Elevated PBT (38 °C) within 24 hours of EVT was significantly associated with an increased incidence of symptomatic intracranial hemorrhage, discharge to hospice or inpatient death, poorer clinical outcome and 3-month mortality, and with less functional independence. Further large-scale, prospective and multicenter trials are needed to confirm these findings.

Keywords
body temperature
symptomatic intracranial hemorrhage
endovascular therapy
ischemic stroke
1. Introduction

Stroke is the second leading cause of mortality worldwide and the third leading cause of patient disability, affecting approximately 1 in 4 people during their lifetime [1]. Endovascular therapy (EVT) has proven to be an effective treatment for patients with acute ischemic stroke (AIS) caused by large vessel occlusion (LVO), with improved outcomes and reduced mortality compared to medical management alone [2, 3]. Following the onset of stroke, about one-third of patients present with sub-febrile fever that can persist for up to 24 hours [4]. The findings in relation to the effects of body temperature on outcomes following AIS are contradictory. Prior studies showed that pyrexia was associated with poorer outcomes and increased short- and long-term mortality after AIS [5, 6, 7, 8, 9]. Increased body temperature within the first 24 hours of ischemic stroke is considered to be a risk factor for hemorrhagic transformation in patients with or without recombinant tissue plasminogen activator (rt-PA) thrombolysis [5, 10, 11]. However, other studies have shown a likely beneficial effect of higher body temperature on clot thrombolysis within the first three hours of hospital admission, and on neurological improvement within a few hours of hospital admission [12]. Moreover, a prospective study on 516 patients who presented with ischemia within 6 hours of stroke-onset found that low body temperature was independently associated with the development of severe ischemic stroke [13]. Only a few studies have examined the effects of post-EVT body temperature on the outcomes from ischemic stroke [14, 15], while the associations between body temperature, clinical outcome and symptomatic intracranial hemorrhage (sICH) following EVT are still unknown. The aim of this study was therefore to investigate for associations between elevated body temperature within 24 hours of EVT for large vessel occlusion stroke and sICH as well as clinical outcomes.

2. Methods

This was a retrospective study of consecutive patients who presented with acute large vessel occlusion stroke and were treated with EVT from August 2018 to June 2021 at a university hospital in China. The inclusion criteria were: patient age 18 years, presentation within 24 hours of the time last seen well (TLSW0), and occlusion of the terminal internal carotid, M1, or M2 segments of the middle cerebral artery or basilar artery. The exclusion criteria were: known or diagnosed infection on the day of stroke, pre-mRS >1, onset of TLSW >24 hours, patients who underwent intra-arterial thrombolysis only without mechanical thrombectomy, reperfusion of the suspected occlusion vessel before thrombectomy, a history of severe respiratory failure or malignant tumor, and lost to follow-up with no 3 month mRS data. Of 97 patients enrolled, 7 were excluded because they received only intra-arterial thrombolysis without thrombectomy, and one because of spontaneous reperfusion. Thus, a total of 89 patients were included in the study.

2.1 Measurement of Body Temperature

The patient’s body temperature was measured using a forehead thermometer. Temperature readings were obtained upon admission and then routinely every 4 hours post-EVT. The peak body temperature (PBT) was recorded as the highest value within 24 hours of EVT. Fever was defined as a body temperature of 37.3 °C [16].

2.2 Data Collection

Patients with ischemic stroke post-EVT were divided into two groups according to the presence or absence of fever (PBT 37.3 °C) within 24 hours of EVT. The following variables were recorded for all patients upon admission: body temperature, age, sex, smoking status, history of atrial fibrillation (AF), diabetes mellitus (DM), chronic kidney disease (CKD), coronary heart disease (CAD), prior stroke, dyslipidemia, initial National Institute of Health Stroke Scale (NIHSS) score, Alberta Stroke Program Early CT Score (ASPECTS), and the pre-treatment modified Rankin Scale (mRS) score. In addition, the 3-month mRS score, stroke type as categorized by the Trial of ORG 10,172 in Acute Stroke Treatment (TOAST) classification, door-to-puncture time (DPT), door-to-recanalization time (DRT), and last-known normal-to-puncture time (LKNPT) times were also recorded. Furthermore, data on clinical evidence of pneumonia, urinary tract infection (UTI), sICH, subarachnoid hemorrhage, thrombolysis in cerebral infarction (TICI), and the mRS score upon discharge were collected. Discharge to palliative care or hospice, and patient deaths were also recorded.

2.3 Evaluation of Clinical Outcomes

Functional clinical outcomes were evaluated using the pre-stroke mRS score upon admission and at 3-months after EVT. Patients were assessed either remotely over the telephone, or in-person during outpatient follow-up. Favorable outcome (functional independence) was defined as an mRS score of 0–2, and poor outcome as an mRS score of 3 or mortality within 3 months of discharge. sICH was defined as any intraparenchymal or intraventricular hemorrhage visible on post-EVT CT that led to a 4-point NIHSS score increase, or that resulted in coma or death [17].

2.4 Statistical Analysis

Statistical analysis was performed using the SPSS Statistics Package (Version 26.0; IBM Corporation, Armonk, NY, USA). Continuous variables were presented as the mean ±SD for normally distributed variables, or as the median with interquartile range (IQR) for non-normally distributed variables. Data were compared using independent samples, T-Test, and statistical analysis, χ2 test, or Fisher’s Exact Test for small, expected frequencies. Multivariable logistic regression models were constructed to calculate odds ratios (ORs) and corresponding 95% CIs. These were used to evaluate the associations between PBT and clinical outcomes in study participants. Statistical significance was defined as a p-value of less than 0.05.

3. Results

A total of 89 consecutive patients (mean age 66.35 ± 12.85 years, of which 74.16% were male) with large vessel occlusion ischemic stroke and who underwent EVT met the study inclusion criteria. Patients were divided into two groups according to their PBT reading within 24 hours of EVT. The clinical characteristics of these two groups are summarized in Table 1. The median NIHSS admission score (IQR) of the overall study group was 16.0 (12.0, 21.0), with a significant difference observed between the two groups (Table 1). No other differences in patient demographics or in baseline ASPECTS were bet between the two groups. Reperfusion (TICI >2b) occurred in 75 (84.3%) of the study patients.

Table 1.Baseline clinical characteristics of patients undergoing EVT.
Total PBT <37.3 °C PBT 37.3 °C χ2/t/z p
Patients 89 34 55
AT, Mean ± SD 36.62 ± 0.61 36.55 ± 0.21 36.66 ± 0.76 –0.977 0.332
Age, Mean ± SD 66.35 ± 12.85 65.82 ± 11.36 66.673 ± 13.78 –0.301 0.764
Male, n, % 66 (74.16) 21 (61.76) 45 (81.82) 4.409 0.036
Female, n, % 23 (25.84) 13 (38.24) 10 (18.18) 4.409 0.036
Hypertension, n, % 55 (61.80) 22 (64.71) 33 (60.00) 0.197 0.657
AF, n, % 35 (39.33) 9 (26.47) 26 (47.27) 3.811 0.051
DM, n, % 17 (19.10) 9 (26.47) 8 (14.55) 1.934 0.164
CAD, n, % 22 (24.72) 7 (20.59) 15 (27.27) 0.505 0.478
Previous Stroke, n, % 21 (23.60) 9 (26.47) 11 (20.00) 0.505 0.477
Dyslipidemia, n, % 13 (14.61) 5 (15.15) 8 (14.82) 0.002 0.966
CKD, n, % 10 (11.24) 3 (8.82) 7 (12.73) 0.321 0.571
Current smoker, n, % 27 (30.34) 13 (38.24) 14 (25.46) 1.624 0.203
NIHSS admission (IQR) 16.0 (12.0, 21.0) 14.0 (10.0, 17.0) 18.0 (13.0, 22.0) –3.032 0.002
ASPECTS pre-treatment (IQR) 8.00 (8.00, 9.00) 8.0 (7.75, 9.00) 8.00 (8.00, 9.00) –0.773 0.44
mRS pre-treatment (IQR) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) –1.009 0.312
PC-stroke, n, % 10 (11.24) 1 (2.9) 9 (16.4) 2.569 0.109
AC-stroke, n, % 79 (88.76) 33 (97.1) 46 (83.6) 2.569 0.109
TOAST
LAA, n, % 39 (43.82) 19 (55.88) 20 (36.36) 4.522 0.340
CE, n, % 40 (44.94) 12 (35.29) 28 (50.91)
SVO, n, % 1 (1.12) 0 (0.00) 1 (1.89)
SOE, n, % 5 (5.62) 1 (2.94) 4 (7.27)
SUE, n, % 4 (4.49) 2(5.88) 2 (3.64)
Bridging rt-PA, n, % 42 (47.19) 12(35.29) 30 (54.55) 3.125 0.077
DPT (IQR), min 150.00 (107.00, 204.00) 121.50 (99.50, 162.25) 177.00 (115.00, 233.00) –2.534 0.011
LKNPT (IQR), min 296.00 (207.00, 490.00) 330.00 (201.50, 556.50) 290.50 (209.25, 437.50) –0.717 0.473
TICI post 2b, n, % 75 (84.27) 31 (91.18) 44 (80.00) 1.98 0.159
Abbreviations: AT, Admission Temperature; AC, Anterior Circulation; AF, Atrial Fibrillation; CE, Cardioembolic; CKD, Chronic Kidney Disease; CAD, Coronary Artery Disease; DM, Diabetes Mellitus; DPT, Door-to-Puncture Time; LAA, Large Artery Atherosclerosis; LKNPT, Last-Known Normal-to-Puncture Time; PBT, Peak Body Temperature; PC, Posterior Circulation; SVO, Small Vessel Occlusion; SOE, Stroke of Other Etiology; SUE, Stroke of Undetermined Etiology; TICI, Thrombolysis in Cerebral Infarction.

The clinical outcomes of the study participants are shown in Table 2. Patients with elevated PBT had a higher mRS score upon discharge (4, IQR 1.5–5) compared to those with normal PBT (2, IQR 1–4; p = 0.002), with 17 (30.9%) requiring discharge to a hospice or palliative care compared to 3 (8.8%) for the normal PBT group (p = 0.015). Overall, 39 (43.8%) patients had a favorable outcome at 3 months post-discharge, with a lower incidence in the high PBT group (30.9%) than in the normal PBT group (64.7%; p = 0.002). The high PBT group showed increased mortality at 3 months post-discharge (45.5% vs 20.6%, respectively; p = 0.018) and a poorer outcome as defined by an mRS of 3 (69.1% vs 35.3%, respectively; p = 0.002). The PBT 37.3 °C group also had a higher sICH than the PBT <37.3 °C group, but this was not statistically significant (p = 0.11).

Table 2.Clinical outcomes of patients with normal or elevated PBT during the first 24 hours after EVT.
Total = 89 PBT <37.3 °C PBT 37.3 °C χ2/t/z p
(n = 34) (n = 55)
Pneumonia, n, % 35 (39.32) 9 (26.47) 26 (47.27) 3.81 0.051
Urinary tract infection, n, % 5 (56.18) 3 (8.82) 2 (3.64) 0.31 0.579
sICH, n, % 15 (16.85) 3 (8.82) 12 (21.82) 2.53 0.112
mRS discharge (IQR) 4 (1.5, 5) 2 (1.00, 4.00) 4 (2.00, 5.00) –3.11 0.002
Inpatient Mortality/hospice discharge, n, % 20 (22.47) 3 (8.82) 17 (30.91) 5.88 0.015
Favorable outcome, n, % 39 (43.82) 22 (64.71) 17 (30.91) 9.75 0.002
Mortality at 3 months, n, % 32 (35.96) 7 (20.59) 25 (45.45) 5.64 0.018
Poor outcome, n, % 50 (56.18) 12 (35.29) 38 (69.09) 9.70 0.002
Favorable outcome: mRS (0–2) at 3 months. Poor outcome: mRS 3. sICH, Symptomatic Intracranial Hemorrhage.

In the group of patients with a PBT between 37.3 °C and 38 °C, no significant associations were found with poor clinical outcome. However, PBT 38 °C was associated with an increased risk of poor clinical outcomes, with an adjusted OR of 25.6 (95% CI: 5.2–126.8; p < 0.001), as shown in Table 3.

Table 3.Association of PBT with poor outcome at 3-months post-discharge.
Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value
<37.3 °C / / / /
37.3 °C PBT <38 °C 1.22 (0.42, 3.54) 0.71 0.90 (0.27, 2.99) 0.871
PBT 38 °C 25.66 (5.19, 126.83) <0.001 12.86 (2.40, 68.78) <0.001
Female 0.73 (0.22, 2.40) 0.606
NIHSS admission 1.14 (1.01, 1.28) 0.024
DPT 1.01 (1.00, 1.01) 0.109

In patients with PBT between 37.3 °C and 38 °C, no association was seen with mortality at 3 months. However, the high PBT group had an increased risk of 3-month mortality, (OR = 6.56, 95% CI: 1.75–24.6; p = 0.01) (Table 4). After adjustment for sex, NIHSS admission scores and DPT, a PBT 38 °C within 24 hours of EVT was associated with an increased risk of sICH (OR = 8.84, 95% CI: 1.70–46.01; p = 0.01) (Table 5). PBT 38 °C within 24 hours of EVT was also associated with an increased risk of in-patient death or hospice discharge (OR = 10.48, 95% CI: 2.04–53.92; p = 0.005) (Table 6).

Table 4.Association of PBT with mortality at 3-months post-discharge.
Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value
<37.3 °C / / / /
37.3 °C PBT <38 °C 1.22 (0.35, 4.20) 0.755 1.52 (0.41, 5.69) 0.533
PBT 38°C 6.66 (2.19, 20.31) 0.001 6.56 (1.75, 24.59) 0.005
Female 1.97 (0.64, 6.11) 0.239
NIHSS admission 1.03 (0.94, 1.13) 0.485
DPT 1.00 (0.99, 1.01) 0.612
Table 5.Association of PBT with sICH.
Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value
PBT <37.3°C / / / /
37.3 °C PBT <38 °C 0.90 (0.13, 5.82) 0.911 1.16 (0.17, 8.01) 0.883
PBT 38 °C 5.17 (1.26, 21.10) 0.022 8.84 (1.70, 46.01) 0.010
Female 0.77 (0.17, 3.42) 0.727
NIHSS admission 0.93 (0.83, 1.04) 0.208
DPT 1.00 (0.99, 1.01) 0.650
Table 6.Association of PBT with inpatient death or hospice discharge.
Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value
PBT <37.3 °C / / / /
37.3 °C PBT <38 °C 1.41 (0.26, 7.64) 0.691 1.16 (0.30, 10.22) 0.530
PBT 38 °C 9.04 (2.26, 36.12) 0.002 10.48 (2.04, 53.92) 0.005
Female 1.61 (0.42, 6.15) 0.488
NIHSS admission 1.04 (0.93, 1.15) 0.518
DPT 1.00 (0.99, 1.01) 0.356
4. Discussion

This study found that elevated PBT (38 °C) within 24 hours of EVT in patients with large vessel occlusion stroke was associated with a higher incidence of discharge to hospice or death, poorer clinical outcome (mRS 3 at 3 months post-discharge), increased 3-month mortality, and less functional independence. In contrast to previous studies that reported no relationship between PBT and the risk of hemorrhagic transformation [14, 15], we found that PBT 38 °C within 24 hours of EVT was associated with an increased risk of sICH. In patients who present with high initial NIHSS, posterior circulation stroke or AF, this may be an indicator of increased severity of disease and thus explain the association with PBT.

The body temperature of patients with ischemic stroke increases in the first 72 hours, with the harmful effects of hyperthermia occurring in the first 48 hours. In contrast, the neuroprotection afforded by hypothermia occurs during the first 24 hours following stroke onset [18]. With cerebral ischemia, increased body temperature leads to subsequent neurotransmitter release, increased metabolic demand, free-radical production, and disruption of the blood-brain barrier [19]. These events increase the risk of brain cell death and lead to a potentially larger cerebral infarct volume and unfavorable clinical outcomes [19, 20]. Higher body temperature was independently associated with major neurological improvement in patients with severe ischemic stroke treated with thrombolysis via rtPA [21].

Inflammatory factors may also play an important role in the elevated temperatures observed following EVT. Following an acute ischemic stroke, inflammatory factors are regarded as an inevitable pathological consequence of post-cerebral ischemia, which can begin within a few minutes and last for days to weeks or even longer [22]. Elevated levels of acute inflammatory response markers, including interleukin-6 (IL-6) and C-reactive protein (CRP), are associated with poor outcomes after stroke [23]. The IL-6 level is independently associated with futile reperfusion in the setting of EVT and with poor outcome [24]. CRP is also independently associated with early complications and with patient outcome following recanalization by EVT [25]. A high neutrophil-lymphocyte ratio (NLR) at admission may predict poorer functional outcomes following EVT in patients with AIS [22]. A low lymphocyte-monocyte ratio (LMR) or high NLR within 24 hours of EVT was also independently associated with poorer functional outcome, whereas the LMR and NLR at admission were not significant predictors of outcome at 3 months [26].

A multicenter randomized controlled trial (The Cooling for Ischemic Stroke Trial, COOLIST) on the effects of hypothermia following ischemic stroke failed to demonstrate any benefit from surface cooling [27]. Mild hypothermia is a precipitating factor for the development of pneumonia, thus reducing its potential therapeutic efficacy [27].

Inadvertent hypothermia following EVT for anterior circulation stroke is not associated with improvement in functional outcome or a reduction in mortality, but with increased risk of bradyarrhythmia and pneumonia [28]. Although therapeutic hypothermia has a positive effect on the molecular pathways of ischemic injury, the benefits from systemic hypothermia remain limited due to the time taken to reach targeted temperatures and to the related complications. Endovascular delivery of hypothermia is a novel approach to cool the affected brain tissue using selective and rapid local control of the local temperature [29]. Maintaining normothermia might be preferable to therapeutic hypothermia in the early phase of post-ischemic stroke. Paracetamol may also have a favorable effect on functional outcomes in patients with higher temperature, but further research is warranted [29, 30, 31]. The maintenance of normal body temperature may therefore be more suitable and safer than hypothermia therapy.

5. Limitations

This was a single-center retrospective study that included anterior and posterior circulation strokes. Data on inflammatory markers such as C-reactive protein was not collected. Prospective, multicenter, large-scale trials are warranted in the future.

6. Conclusions

This study found that elevated PBT (38 °C) within 24 hours of EVT was significantly associated with a higher incidence of discharge to hospice or inpatient death, poorer clinical outcome, higher 3-month mortality, lower incidence of functional independence, and increased risk of symptomatic intracranial hemorrhage. Prospective, multicenter, large-scale trials are warranted to confirm these findings.

Author Contributions

YC, BC, and SY conceived and designed the study. YC, SY, BC, TNN, MM, MA, and JWellington drafted the manuscript. ZY, WL, and GC performed the surgery. ZY, GC, WL, JWu, DL, and JL collected the data and followed up with patients. SY, YC, and BC analyzed and interpreted the data. All authors discussed, edited, and approved the final manuscript.

Ethics Approval and Consent to Participate

The study was approved by Foshan Sanshui District People’s Hospital review board (shengwei202105) and individual consent for this retrospective analysis was waived. Written informed consent was not required due to the retrospective nature of the study and the blinded data acquisition.

Acknowledgment

We appreciate patients’ contributions and colleagues at the study.

Funding

The projected is supported by Foshan Medical Technology Innovation Platform Construction Foundation, China (FS0AA-KJ218-1301-0012).

Conflict of Interest

The authors declare no conflict of interest.

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
[1]
Campbell BCV, Khatri P. Stroke. The Lancet. 2020; 396: 129–142.
[2]
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016; 387: 1723–1731.
[3]
Eskey CJ, Meyers PM, Nguyen TN, Ansari SA, Jayaraman M, McDougall CG, et al. Indications for the Performance of Intracranial Endovascular Neurointerventional Procedures: a Scientific Statement from the American Heart Association. Circulation. 2018; 137: e661–e689.
[4]
den Hertog HM, van der Worp HB, van Gemert HMA, Algra A, Kappelle LJ, van Gijn J, et al. An early rise in body temperature is related to unfavorable outcome after stroke: data from the PAIS study. Journal of Neurology. 2011; 258: 302–307.
[5]
Leira R, Sobrino T, Blanco M, Campos F, Rodríguez-Yáñez M, Castellanos M, et al. A higher body temperature is associated with haemorrhagic transformation in patients with acute stroke untreated with recombinant tissue-type plasminogen activator (rtPA). Clinical Science. 2012; 122: 113–119.
[6]
Prasad K, Krishnan PR. Fever is associated with doubling of odds of short-term mortality in ischemic stroke: an updated meta-analysis. Acta Neurologica Scandinavica. 2010; 122: 404–408.
[7]
Tiainen M, Meretoja A, Strbian D, Suvanto J, Curtze S, Lindsberg PJ, et al. Body Temperature, Blood Infection Parameters, and Outcome of Thrombolysis-Treated Ischemic Stroke Patients. International Journal of Stroke. 2013; 8: 632–638.
[8]
Hajat C, Hajat S, Sharma P. Effects of Poststroke Pyrexia on Stroke Outcome: A meta-analysis of studies in patients. Stroke. 2000; 31: 410–414.
[9]
Kammersgaard LP, Jørgensen HS, Rungby JA, Reith J, Nakayama H, Weber UJ, et al. Admission Body Temperature Predicts Long-Term Mortality after Acute Stroke. Stroke. 2002; 33: 1759–1762.
[10]
Ueno T, Nishijima H, Hikichi H, Haga R, Arai A, Suzuki C, et al. Association of survival and hyperthermia after rt-PA for ischemic stroke. Acta Neurologica Scandinavica. 2018; 138: 574–578.
[11]
Millán M, Grau L, Castellanos M, Rodríguez-Yáñez M, Arenillas JF, Nombela F, et al. Body temperature and response to thrombolytic therapy in acute ischaemic stroke. European Journal of Neurology. 2008; 15: 1384–1389.
[12]
Khanevski AN, Naess H, Thomassen L, Waje-Andreassen U, Nacu A, Kvistad CE. Elevated body temperature in ischemic stroke associated with neurological improvement. Acta Neurologica Scandinavica. 2017; 136: 414–418.
[13]
Kvistad CE, Thomassen L, Waje-Andreassen U, Naess H. Low body temperature associated with severe ischemic stroke within 6 hours of onset: The Bergen NORSTROKE Study. Vascular Health and Risk Management. 2012; 8: 333–338.
[14]
Chen M, Fang J, Wu X, Liu Q, Feng L, He L. Association between hyperpyrexia and poststroke outcomes in patients with recanalization after mechanical thrombectomy: a retrospective cohort study. BMC Neurology. 2021; 21: 365.
[15]
Diprose WK, Liem B, Wang MTM, Sutcliffe JA, Brew S, Caldwell JR, et al. Impact of Body Temperature before and after Endovascular Thrombectomy for Large Vessel Occlusion Stroke. Stroke. 2020; 51: 1218–1225.
[16]
Grünebaum A, Chervenak FA, McCullough LB, Dudenhausen JW, Bornstein E, Mackowiak PA. How fever is defined in COVID-19 publications: a disturbing lack of precision. Journal of Perinatal Medicine. 2021; 49: 255–261.
[17]
Hacke W, Kaste M, Bluhmki E. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. Journal of Vascular Surgery. 2008; 48: 1634–1635.
[18]
Blanco M, Campos F, Rodríguez-Yáñez M, Arias S, Fernández-Ferro J, Gómez-Sánchez JC, et al. Neuroprotection or increased brain damage mediated by temperature in stroke is time dependent. PLoS ONE. 2012; 7: e30700.
[19]
Ginsberg MD, Busto R. Combating Hyperthermia in Acute Stroke: A significant clinical concern. Stroke. 1998; 29: 529–534.
[20]
Geurts M, Scheijmans FEV, van Seeters T, Biessels GJ, Kappelle LJ, Velthuis BK, et al. Temporal profile of body temperature in acute ischemic stroke: relation to infarct size and outcome. BMC Neurology. 2016; 16: 233.
[21]
Kvistad CE, Thomassen L, Waje-Andreassen U, Logallo N, Naess H. Body temperature and major neurological improvement in tPA-treated stroke patients. Acta Neurologica Scandinavica. 2014; 129: 325–329.
[22]
Chen Z, He Y, Su Y, Sun Y, Zhang Y, Chen H. Association of inflammatory and platelet volume markers with clinical outcome in patients with anterior circulation ischaemic stroke after endovascular thrombectomy. Neurological Research. 2021; 43: 503–510.
[23]
Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLOS Medicine. 2009; 6: e1000145.
[24]
Mechtouff L, Bochaton T, Paccalet A, Da Silva CC, Buisson M, Amaz C, et al. Association of Interleukin-6 Levels and Futile Reperfusion after Mechanical Thrombectomy. Neurology. 2021; 96: e752–e757.
[25]
Zang N, Lin Z, Huang K, Pan Y, Wu Y, Wu Y, et al. Biomarkers of Unfavorable Outcome in Acute Ischemic Stroke Patients with Successful Recanalization by Endovascular Thrombectomy. Cerebrovascular Diseases. 2020; 49: 583–592.
[26]
Lux D, Alakbarzade V, Bridge L, Clark CN, Clarke B, Zhang L, et al. The association of neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio with 3-month clinical outcome after mechanical thrombectomy following stroke. Journal of Neuroinflammation. 2020; 17: 60.
[27]
Geurts M, Petersson J, Brizzi M, Olsson-Hau S, Luijckx G, Algra A, et al. COOLIST (Cooling for Ischemic Stroke Trial): A multicenter, open, randomized, phase II, clinical trial: A multicenter, open, randomized, phase II, clinical trial. Stroke. 2017; 48: 219–221.
[28]
Hartmann C, Winzer S, Pallesen L, Prakapenia A, Siepmann T, Moustafa H, et al. Inadvertent hypothermia after endovascular therapy is not associated with improved outcome in stroke due to anterior circulation large vessel occlusion. European Journal of Neurology. 2021; 28: 2479–2487.
[29]
Choi JH, Poli S, Chen M, Nguyen TN, Saver JL, Matouk C, et al. Selective brain hypothermia in acute ischemic stroke: Reperfusion without reperfusion injury. Frontiers in Neurology. 2020; 11: 594289.
[30]
Middleton S, McElduff P, Ward J, Grimshaw JM, Dale S, D’Este C, et al. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. The Lancet. 2011; 378: 1699–1706.
[31]
den Hertog HM, van der Worp HB, van Gemert HMA, Algra A, Kappelle LJ, van Gijn J, et al. The Paracetamol (Acetaminophen) in Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. The Lancet Neurology. 2009; 8: 434–440.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Share
Back to top